American Renal Associates Holdings Inc (NYSE:ARA) has earned a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $21.00.

Several equities analysts have weighed in on the company. Zacks Investment Research raised American Renal Associates from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. SunTrust Banks reaffirmed a “buy” rating and issued a $25.00 target price on shares of American Renal Associates in a research report on Thursday, August 9th. ValuEngine raised American Renal Associates from a “hold” rating to a “buy” rating in a research report on Friday, August 3rd. Goldman Sachs Group assumed coverage on American Renal Associates in a research report on Thursday, July 19th. They issued a “neutral” rating and a $16.00 target price for the company. Finally, Leerink Swann reiterated a “market perform” rating and issued a $22.00 price objective (down previously from $27.00) on shares of American Renal Associates in a research note on Wednesday, April 25th.

NYSE ARA traded down $0.03 during trading on Monday, hitting $20.76. The stock had a trading volume of 94,373 shares, compared to its average volume of 162,262. The company has a market cap of $682.78 million, a P/E ratio of 34.03, a P/E/G ratio of 1.36 and a beta of 1.96. The company has a debt-to-equity ratio of 5.30, a current ratio of 1.07 and a quick ratio of 1.04. American Renal Associates has a twelve month low of $9.91 and a twelve month high of $24.07.

American Renal Associates (NYSE:ARA) last released its earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.03. The company had revenue of $217.18 million during the quarter, compared to the consensus estimate of $203.70 million. American Renal Associates had a positive return on equity of 19.60% and a negative net margin of 1.11%. analysts anticipate that American Renal Associates will post 0.6 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in ARA. Bank of New York Mellon Corp boosted its stake in shares of American Renal Associates by 15.9% in the 4th quarter. Bank of New York Mellon Corp now owns 47,762 shares of the company’s stock valued at $831,000 after buying an additional 6,536 shares during the period. BlackRock Inc. boosted its stake in shares of American Renal Associates by 6.2% in the 4th quarter. BlackRock Inc. now owns 630,825 shares of the company’s stock valued at $10,977,000 after buying an additional 37,034 shares during the period. Deutsche Bank AG boosted its stake in shares of American Renal Associates by 68.3% in the 4th quarter. Deutsche Bank AG now owns 40,873 shares of the company’s stock valued at $710,000 after buying an additional 16,582 shares during the period. Two Sigma Investments LP purchased a new position in shares of American Renal Associates in the 4th quarter valued at about $437,000. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of American Renal Associates by 206.3% in the 4th quarter. TIAA CREF Investment Management LLC now owns 78,444 shares of the company’s stock valued at $1,365,000 after buying an additional 52,837 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Further Reading: Fundamental Analysis and Choosing Stocks

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.